Accord EMENA Chief Says Industry Is Pushing Back On Pressures

Inflation, Pricing Constraints And Shortages Follow Fallout From Pandemic

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

Amid continuing cost inflation, downwards pressure on prices, industry shortages and other supply-chain disruptions, Paul Tredwell – Accord’s executive vice-president for the Europe, Middle East and North Africa region – talks about how the off-patent industry is seeking to improve its operating environment.

Europe at night seen from space
Europe’s off-patent industry is dealing with multiple pressures • Source: Shutterstock

Having set out to Generics Bulletin his overall approach to Accord’s business since taking over as executive vice-president for the Europe, Middle East and North Africa region (Also see "Accord Unveils New Ventures After A Year Of Change" - Generics Bulletin, 28 November, 2022.) – as well as delving into detail on the unique positioning offered by the firm’s broad portfolio (see sidebar) – Paul Tredwell turned his eye to regulatory and market challenges in the final part of an exclusive interview.

Touching on issues including the squeeze caused by pricing pressures and cost inflation, the risks of supply-chain fragility and shortages,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Regulation

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes

 
• By Urtė Fultinavičiūtė and Reed Miller

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

Sawai Outlook Improves But Japanese Generics Continue To Suffer Under NHI Price Cuts

 
• By Chloe Kent

Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.

Kashiv Finishes Patient Recruitment In Late Stage Xolair Biosimilar Trial

 
• By Adam

Following on from its recently announced US licensing deal with Amneal over its Xolair biosimilar, Kashiv has finished patient recruitment for a trial for the omalizumab candidate, paving the way for submissions.

More from Policy & Regulation

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Sawai Outlook Improves But Japanese Generics Continue To Suffer Under NHI Price Cuts

 
• By Chloe Kent

Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.

Biden Launches Effort To Strengthen US Pharmaceutical Supply Chain

 
• By Bowman Cox

A fresh executive order from US president Joe Biden calls for short-term and long-term study, broad consultation, and co-ordination with allies on the domestic supply chain.